Recent Advances in Cancer Stem Cell-Targeted Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Mar 8

PMID 30841635

Citations 39

Authors

Narayanasamy Badrinath

So Young Yoo

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors, CSCs have to be targeted. Recent advances in immunotherapies have shown promising outcomes in curing cancer, which are also applicable to target CSCs. CSCs express immune markers and exhibit specific immune characteristics in various cancers, which can be used in immunotherapies to target CSCs in the tumor microenvironment. Recently, various strategies have been used to target CSCs. Adaptive T-cells, dendritic cell (DC)-based vaccines, oncolytic viruses, immune checkpoint inhibitors, and combination therapies are now being used to target CSCs. Here, we discuss the feasibility of these immunological approaches and the recent trends in immunotherapies to target CSCs.

Citing Articles

Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies.

El-Tanani M, Rabbani S, Satyam S, Rangraze I, Wali A, El-Tanani Y Cancers (Basel). 2025; 17(3).

PMID: 39941751 PMC: 11815874. DOI: 10.3390/cancers17030382.

Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells.

Farhangnia P, Ghods R, Falak R, Zarnani A, Delbandi A Discov Oncol. 2024; 15(1):251.

PMID: 38943028 PMC: 11213845. DOI: 10.1007/s12672-024-01121-x.

An overview of current research on cancer stem cells: a bibliometric analysis.

Zhang X, Du W, Huang X, Zhong H, Hu N Clin Transl Oncol. 2024; 26(10):2466-2478.

PMID: 38625493 DOI: 10.1007/s12094-024-03486-5.

Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting.

Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W Genes Dis. 2024; 11(3):101043.

PMID: 38292177 PMC: 10825311. DOI: 10.1016/j.gendis.2023.05.024.

Targeting cancer stem cell plasticity in triple-negative breast cancer.

Guo Z, Han S Explor Target Antitumor Ther. 2024; 4(6):1165-1181.

PMID: 38213533 PMC: 10776602. DOI: 10.37349/etat.2023.00190.

References

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M . Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2008; 1(3):313-23. DOI: 10.1016/j.stem.2007.06.002. View

Todaro M, Perez Alea M, Di Stefano A, Cammareri P, Vermeulen L, Iovino F . Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2008; 1(4):389-402. DOI: 10.1016/j.stem.2007.08.001. View

Zhang S, Balch C, Chan M, Lai H, Matei D, Schilder J . Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-20. PMC: 2553722. DOI: 10.1158/0008-5472.CAN-08-0364. View

Ginestier C, Liu S, Diebel M, Korkaya H, Luo M, Brown M . CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010; 120(2):485-97. PMC: 2810075. DOI: 10.1172/JCI39397. View

Wei J, Barr J, Kong L, Wang Y, Wu A, Sharma A . Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010; 16(2):461-73. PMC: 2943842. DOI: 10.1158/1078-0432.CCR-09-1983. View

Schatton T, Schutte U, Frank N, Zhan Q, Hoerning A, Robles S . Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010; 70(2):697-708. PMC: 2883769. DOI: 10.1158/0008-5472.CAN-09-1592. View

Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A . Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010; 16(3):800-13. PMC: 2842003. DOI: 10.1158/1078-0432.CCR-09-2730. View

10.

Trerotola M, Rathore S, Goel H, Li J, Alberti S, Piantelli M . CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res. 2010; 2(2):135-44. PMC: 2855629. View

11.

Shackleton M . Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. 2010; 20(2):85-92. DOI: 10.1016/j.semcancer.2010.04.002. View

12.

Wu A, Wei J, Kong L, Wang Y, Priebe W, Qiao W . Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12(11):1113-25. PMC: 3098021. DOI: 10.1093/neuonc/noq082. View

13.

Lin W, Karsten U, Goletz S, Cheng R, Cao Y . Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol. 2010; 92(2):97-105. PMC: 3081512. DOI: 10.1111/j.1365-2613.2010.00747.x. View

14.

Iliopoulos D, Hirsch H, Wang G, Struhl K . Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011; 108(4):1397-402. PMC: 3029760. DOI: 10.1073/pnas.1018898108. View

15.

Yeung T, Gandhi S, Bodmer W . Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2011; 108(11):4382-7. PMC: 3060223. DOI: 10.1073/pnas.1014519107. View

16.

Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J . Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012; 72(7):1853-64. PMC: 3320735. DOI: 10.1158/0008-5472.CAN-11-1400. View

17.

Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G . HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol. 2012; 250(1-2):27-34. DOI: 10.1016/j.jneuroim.2012.05.010. View

18.

Wang H, Chen N, Minev B, Szalay A . Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med. 2012; 10:167. PMC: 3478222. DOI: 10.1186/1479-5876-10-167. View

19.

Fujimori H, Shikanai M, Teraoka H, Masutani M, Yoshioka K . Induction of cancerous stem cells during embryonic stem cell differentiation. J Biol Chem. 2012; 287(44):36777-91. PMC: 3481281. DOI: 10.1074/jbc.M112.372557. View

20.

Kemper K, Prasetyanti P, de Lau W, Rodermond H, Clevers H, Medema J . Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells. 2012; 30(11):2378-86. DOI: 10.1002/stem.1233. View